Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Sold by Frontier Capital Management Co. LLC

Frontier Capital Management Co. LLC reduced its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 61.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 150,172 shares of the company's stock after selling 242,091 shares during the period. Frontier Capital Management Co. LLC owned about 0.23% of Kymera Therapeutics worth $6,041,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. JPMorgan Chase & Co. increased its holdings in Kymera Therapeutics by 212.6% in the third quarter. JPMorgan Chase & Co. now owns 140,491 shares of the company's stock valued at $6,649,000 after buying an additional 95,547 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in shares of Kymera Therapeutics by 5.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 387,187 shares of the company's stock valued at $15,577,000 after purchasing an additional 20,346 shares in the last quarter. Victory Capital Management Inc. raised its holdings in Kymera Therapeutics by 174.2% in the 4th quarter. Victory Capital Management Inc. now owns 19,899 shares of the company's stock worth $801,000 after purchasing an additional 12,643 shares during the period. Wells Fargo & Company MN boosted its position in Kymera Therapeutics by 51.8% during the fourth quarter. Wells Fargo & Company MN now owns 21,939 shares of the company's stock worth $883,000 after purchasing an additional 7,487 shares in the last quarter. Finally, Teacher Retirement System of Texas boosted its position in Kymera Therapeutics by 35.8% during the fourth quarter. Teacher Retirement System of Texas now owns 11,490 shares of the company's stock worth $462,000 after purchasing an additional 3,026 shares in the last quarter.

Insider Activity

In related news, CFO Bruce N. Jacobs sold 7,035 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total value of $214,215.75. Following the sale, the chief financial officer now owns 201,886 shares of the company's stock, valued at $6,147,428.70. This trade represents a 3.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Ellen Chiniara sold 2,241 shares of the stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $68,238.45. Following the completion of the sale, the insider now directly owns 80,085 shares in the company, valued at approximately $2,438,588.25. This represents a 2.72% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 10,659 shares of company stock worth $324,567. 15.82% of the stock is currently owned by company insiders.

Kymera Therapeutics Stock Down 3.2%

KYMR stock traded down $1.03 during midday trading on Tuesday, hitting $31.14. The company's stock had a trading volume of 442,700 shares, compared to its average volume of 565,307. The firm has a 50-day simple moving average of $29.58 and a 200-day simple moving average of $37.41. The firm has a market capitalization of $2.03 billion, a P/E ratio of -13.31 and a beta of 2.18. Kymera Therapeutics, Inc. has a 52-week low of $19.45 and a 52-week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its earnings results on Friday, May 9th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.92) by $0.10. Kymera Therapeutics had a negative return on equity of 24.96% and a negative net margin of 191.26%. The firm had revenue of $22.10 million during the quarter, compared to analyst estimates of $11.38 million. During the same period last year, the business posted ($0.69) earnings per share. Kymera Therapeutics's revenue was up 114.6% compared to the same quarter last year. On average, sell-side analysts expect that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on KYMR. Guggenheim restated a "buy" rating and issued a $52.00 price objective on shares of Kymera Therapeutics in a research report on Monday. Citigroup initiated coverage on shares of Kymera Therapeutics in a research report on Thursday, March 13th. They set a "buy" rating and a $52.00 price target on the stock. UBS Group lowered their price objective on Kymera Therapeutics from $72.00 to $70.00 and set a "buy" rating for the company in a research report on Tuesday. Bank of America reduced their target price on Kymera Therapeutics from $47.00 to $44.00 and set a "neutral" rating on the stock in a research report on Monday. Finally, HC Wainwright increased their price target on Kymera Therapeutics from $54.00 to $60.00 and gave the stock a "buy" rating in a report on Friday, February 28th. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $55.27.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.